2. Search Result
Search Result
Results for "

diabetic neuropathy

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

1

Biochemical Assay Reagents

2

Peptides

1

Inhibitory Antibodies

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116239
    Zenarestat

    		Aldose Reductase Neurological Disease Metabolic Disease
    Zenarestat is a potent and orally active aldose reductase inhibitor. Zenarestat improves diabetic peripheral neuropathy in Zucker diabetic fatty rats .
    Zenarestat
  • HY-12883
    PF 05089771
    3 Publications Verification

    		 Sodium Channel Neurological Disease
    PF 05089771 is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor, with IC50 values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNav1.7, cynNav1.7, dogNav1.7, ratNav1.7, and musNav1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy .
    PF 05089771
  • HY-P9970
    Infliximab
    Maximum Cited Publications
    11 Publications Verification

    Avakine; CT-P13

    		 TNF Receptor Bacterial Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research .
    Infliximab
  • HY-66009
    Epalrestat
    3 Publications Verification

    ONO2235

    		 Aldose Reductase Metabolic Disease Inflammation/Immunology Cancer
    Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .
    Epalrestat
  • HY-B1202
    Alrestatin
    1 Publications Verification

    AY-22284

    		 Aldose Reductase Endocrinology
    Alrestatin is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
    Alrestatin
  • HY-105485
    FR-62765

    		Others Neurological Disease Metabolic Disease
    FR-62765 is a derivative of WF-3681. FR-62765 can significantly inhibit the accumulation of sorbitol in the sciatic nerve and the decrease of motor nerve conduction velocity in the tail of diabetic neuropathy rats, which can be used in the research of diabetic neuropathy .
    FR-62765
  • HY-14897
    Rezatomidine

    AGN-203818

    		 Adrenergic Receptor Neurological Disease Metabolic Disease
    Rezatomidine (AGN-203818) is a potent and selective α2-AR agonist. Rezatomidine can be used for diabetic neuropathy and neuropathic pain research .
    Rezatomidine
  • HY-161873
    PW507

    		Sigma Receptor Neurological Disease
    PW507 is a potent, brain-penetrant and selective sigma 1 receptor (S1R) antagonist with a Ki of 7.5 nM for human S1R. PW507 displays a low binding affinity to S2R and hERG. PW507 can be used for the study of painful diabetic neuropathy (PDN) .
    PW507
  • HY-12883B
    PF 05089771 tosylate

    		Sodium Channel Neurological Disease
    PF 05089771 tosylate is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor, with IC50 values of 11 nM, 12 nM, 13 nM, 171 nM and 8 nM for hNav1.7, cynNav1.7, dogNav1.7, ratNav1.7, and musNav1.7, respectively. PF 05089771 is under the study for pain and diabetic neuropathy .
    PF 05089771 tosylate
  • HY-122963
    Danshenol B

    		Adenosine Receptor Metabolic Disease
    Danshenol B is a diterpenoid. Danshenol B has strong aldose reductase (AR) inhibitory activity with IC50 value of 0.042μM. Danshenol B can be used for the research of diabetic related complication resulted by metabolic abnormality, such as cataracts, retinopathy, neuropathy, and nephropathy .
    Danshenol B
  • HY-B1202A
    Alrestatin sodium

    AY-22284A

    		 Aldose Reductase Endocrinology
    Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
    Alrestatin sodium
  • HY-W653944
    Epalrestat-d5

    ONO2235-d5

    		 Isotope-Labeled Compounds Aldose Reductase Metabolic Disease
    Epalrestat-d5 is deuterium labeled Epalrestat. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .
    Epalrestat-d5
  • HY-109156
    Pregabalin arenacarbil

    		GABA Receptor Metabolic Disease
    Pregabalin arenacarbil is a proagent of Pregabalin.Pregabalin is an analog of gamma-aminobutyric acid (GABA) for the research of post herpetic neuralgia, peripheral diabetic neuropathy,fibromyalgia and epilepsy .
    Pregabalin arenacarbil
  • HY-W127737
    Methylcobalamin hydrate

    Mecobalamin hydrate

    		 Biochemical Assay Reagents Others
    Methylcobalamin Hydrate is a coenzyme required for methionine biosynthesis. Vitamins (hematopoiesis). It acts as a histamine receptor, Alzheimer study. Methylcobalamin is also used in the research of peripheral neuropathy, diabetic neuropathy, and as an initial research for amyotrophic lateral sclerosis. It can be used to prevent or research pathologies caused by vitamin B12 deficiency, such as pernicious anemia.
    Methylcobalamin hydrate
  • HY-66009R
    Epalrestat (Standard)

    		Aldose Reductase Metabolic Disease Inflammation/Immunology Cancer
    Epalrestat (Standard) is the analytical standard of Epalrestat. This product is intended for research and analytical applications. Epalrestat is an orally active aldose reductase inhibitor that acts on diabetic neuropathy .
    Epalrestat (Standard)
  • HY-119519
    OB-2

    		Others Neurological Disease
    OB-2 is a STOML3 oligomerization blocker. OB-2 reverses pathological mechanical hypersensitivity. OB-2 can be used for research of painful diabetic neuropathy in mice .
    OB-2
  • HY-138257A
    (R)-Indeloxazine benzenesulfonate

    AS1069562; (R)-YM-08054 benzenesulfonate

    		 5-HT Receptor Serotonin Transporter Neurological Disease Metabolic Disease
    (R)-Indeloxazine benzenesulfonate (AS1069562) is an orally active 5-HT and NE reuptake inhibitor, with IC50 values of 0.35 μM and 3.3 μM, respectively. (R)-Indeloxazine benzenesulfonate (AS1069562) possesses curative-like analgesic effect. (R)-Indeloxazine benzenesulfonate (AS1069562) might improve nerve function impairment via the amelioration of neurotrophic support .
    (R)-Indeloxazine benzenesulfonate
  • HY-145559
    Cemdomespib

    KU-596

    		 HSP Metabolic Disease
    Cemdomespib (KU-596) is a highly bioavailable second-generation Hsp90 modulator. Cemdomespib has shown efficacy in improving sensory deficits in models of diabetic peripheral neuropathy. Cemdomespib induces Hsp70 levels and manifest neuroprotective activity through induction of the heat shock response .
    Cemdomespib
  • HY-P5865
    Tap1a

    Theraphotoxin-Tap1a; TRTX-Tap1a; µ/ω-TRTX-Tap1a

    		 Sodium Channel Neurological Disease
    Tap1a (Theraphotoxin-Tap1a) is a spider venom peptide that inhibits sodium channels with IC50s of 80 nM and 301 nM against Nav1.7 and Nav1.1, respectively. Tap1a shows analgesic effects .
    Tap1a
  • HY-122671
    OB-1

    		Others Neurological Disease
    OB-1 is a stomatin-like protein-3 (STOML3) oligomerization blocker. OB-1 is an effective inhibitor of the self-association of Stomatin, STOML1 and STOML2, but not podocin .
    OB-1
  • HY-Y0790
    Cuminaldehyde

    p-Isopropylbenzaldehyde

    		 Endogenous Metabolite Apoptosis DNA/RNA Synthesis α-synuclein Lipoxygenase Opioid Receptor Interleukin Related TNF Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL), α-glucosidase (IC50=0.5 mg/mL) and lipoxygenase (IC50=1370 μM). Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
    Cuminaldehyde
  • HY-129380
    Fructosyl-lysine
    1 Publications Verification

    Fructoselysine

    		 Endogenous Metabolite Metabolic Disease
    Fructosyl-lysine (Fructoselysine) is an amadori glycation product from the reaction of glucose and lysine by the Maillard reaction. Fructosyl-lysine is the precursor to glucosepane, a lysine–arginine protein cross-link that can be an indicator in diabetes detection .
    Fructosyl-lysine
  • HY-129380A
    Fructosyl-lysine dihydrochloride
    1 Publications Verification

    Fructoselysine dihydrochloride

    		 Endogenous Metabolite Metabolic Disease
    Fructosyl-lysine (Fructoselysine) dihydrochloride is an amadori glycation product from the reaction of glucose and lysine by the Maillard reaction. Fructosyl-lysine dihydrochloride is the precursor to glucosepane, a lysine–arginine protein cross-link that can be an indicator in diabetes detection .
    Fructosyl-lysine dihydrochloride
  • HY-Y0790R
    Cuminaldehyde (Standard)

    		Endogenous Metabolite Apoptosis DNA/RNA Synthesis α-synuclein Lipoxygenase Opioid Receptor Interleukin Related TNF Receptor Infection Neurological Disease Inflammation/Immunology Cancer
    Cuminaldehyde (Standard) is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL) and α-glucosidase (IC50=0.5 mg/mL). Cuminaldehyde can modulate α-synuclein fibrils. Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
    Cuminaldehyde (Standard)
  • HY-W027553
    Ipidacrine

    NIK-247 free base

    		 Cholinesterase (ChE) Potassium Channel Sodium Channel Neurological Disease Metabolic Disease
    Ipidacrine is orally active and brain-penetrant AChE and BuChE inhibitors with IC50 values of 1 μM and 1.9 μM, respectively, which is also a partial agonist of M2-cholinergic receptors and a reversible cholinesterase inhibitor. Ipidacrine has a stimulating effect on neuromuscular transmission and excitation along the nerve fibres with a moderately anti-pain effect. Ipidacrine is an aminopyridines and is structurally similar to Tacrine (HY-111338). Ipidacrine is effective in various amnesia models, improves erectile function and inhibits K + and Na +-channels in the neuronal membrane in diabetic rats. Ipidacrine is promising for research of Alzheimer’s disease, ischaemic stroke, idiopathic neuropathy of the facial nerve, diabetes mellitus-induced erectile dysfunction and other deficits in central or peripheral cholinergic deseases .
    Ipidacrine
  • HY-136535
    Anizatrectinib

    hTrkA-IN-1

    		 Trk Receptor Inflammation/Immunology
    Anizatrectinib (hTrkA-IN-1) is a potent and orally active inhibitor of TrkA kinase with an IC50 of 1.3 nM, compound 2 extracted from patent WO2015175788. Anizatrectinib can be used for the study of inflammatory disease, such as prostatitis, pelvic, et al .
    Anizatrectinib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: